Bausch Health investigated by US Department of Justice over misleading marketing

Three plaque psoriasis drugs and one fungal treatment are the suspects in a case concerning wrongful marketing by Canadian pharmaceutical firm Bausch Health, and the US Department of Justice is reportedly looking into the matter.

Bausch Health has run into problems with the US authorities, as the Canadian company is being investigated for having marketed three plaque psoriasis treatments and one fungal treatment for unintended use, media Endpoints News reports based on a Stat News story.

According to documents seen by Stat News, Bausch is intending to comply with the probe by the US Department of Justice (DOJ), although the uses of the drugs that the investigation concerns are not specified. Bausch Health leadership has therefore instructed employees to preserve all documents and communications, a move known as a ”legal hold.”

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs